CEO Clips - Unicycive Therapeutics: Innovation to Improve Quality of Life For Patients Suffering from Kidney Diseases
Developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
UNI-494 is a patented pro-drug of nicorandil which is currently in development for the treatment of AKI. Nicorandil has been shown in preclinical models to improve mitochondrial function by blocking the opening of MPTP pores in the inner mitochondrial membrane.
Renazorb is an advanced phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia. We have completed a clinical trial studying Renazorb in 32 healthy volunteers. In this study Renazorb was minimally absorbed to the systemic circulation and was safe and well-tolerated at doses up to 6000 mg/day. Renazorb significantly reduced urine phosphate excretion and significantly increased fecal phosphate excretion at doses at and above 3000 mg/day.
For more information on Unicycive Therapeutics Inc. (NASDAQ: UNCY) please click the request investor info button.